Effect of treatment periods on efficacy of glecaprevir and pibrentasvir in chronic hepatitis C: A nationwide, prospective, multicenter study

被引：0

作者：

Morita, Atsuhiro ^{[1
]}

Tamaki, Nobuharu ^{[3
]}

Kobashi, Haruhiko ^{[5
]}

Mori, Nami ^{[6
,7
]}

Tsuji, Keiji ^{[6
,7
]}

Takaki, Shintaro ^{[6
,7
]}

Hasebe, Chitomi ^{[8
]}

Akahane, Takehiro ^{[9
]}

Ochi, Hironori ^{[10
]}

Mashiba, Toshie ^{[10
]}

Urawa, Naohito ^{[23
]}

Fujii, Hideki ^{[2
]}

Mitsuda, Akeri ^{[12
]}

Kondo, Masahiko ^{[13
]}

Ogawa, Chikara ^{[14
]}

Uchida, Yasushi ^{[15
]}

Narita, Ryoichi ^{[16
]}

Marusawa, Hiroyuki ^{[17
]}

Kubotsu, Yoshihito ^{[18
]}

Matsushita, Tomomichi ^{[19
]}

Shigeno, Masaya ^{[20
]}

Yoshida, Hideo ^{[4
]}

Tanaka, Katsuaki ^{[21
]}

Okamoto, Eisuke ^{[22
]}

Kasai, Toyotaka ^{[11
]}

Ishii, Toru ^{[24
]}

Okada, Kazuhiko ^{[25
]}

Kurosaki, Masayuki ^{[3
]}

Izumi, Namiki ^{[3
]}

机构：

[1] Japanese Red Cross Kyoto Daini, Dept Gastroenterol, Kyoto, Japan

[2] Japanese Red Cross Kyoto Daiichi Hosp, Dept Gastroenterol, Kyoto, Japan

[3] Musashino Red Cross Hosp, Dept Gastroenterologyand Hepatol, 1-26-1 Kyonan Cho, Musashino, Tokyo 1808610, Japan

[4] Japanese Red Cross Med Ctr, Dept Gastroenterol, Tokyo, Japan

[5] Japanese Red Cross Okayama Hosp, Dept Gastroenterol, Tokyo, Japan

[6] Hiroshima Red Cross Hosp, Dept Gastroenterol, Hiroshima, Japan

[7] Atom Bomb Survivors Hosp, Hiroshima, Japan

[8] Japanese Red Cross Asahikawa Hosp, Dept Gastroenterol, Asahikawa, Japan

[9] Ishinomaki Red Cross Hosp, Dept Gastroenterol, Ishinomaki, Japan

[10] Matsuyama Red Cross Hosp, Ctr Liver Biliary Pancreat Dis, Matsuyama, Japan

[11] Ise Red Cross Hosp, Dept Gastroenterol & Hepatol, Ise, Japan

[12] Tottori Red Cross Hosp, Dept Gastroenterol, Tottori, Japan

[13] Otsu Red Cross Hosp, Dept Gastroenterol, Otsu, Japan

[14] Takamatsu Red Cross Hosp, Dept Gastroenterol & Hepatol, Takamatsu, Japan

[15] Matsue Red Cross Hosp, Dept Gastroenterol, Matsue, Japan

[16] Oita Red Cross Hosp, Dept Gastroenterol, Oita, Japan

[17] Osaka Red Cross Hosp, Dept Gastroenterol & Hepatol, Osaka, Japan

[18] Karatsu Red Cross Hosp, Dept Internal Med, Saga, Japan

[19] Japanese Red Cross Gifu Hosp, Dept Gastroenterol, Gifu, Japan

[20] Japanese Red Cross Nagasaki Genbaku Hosp, Dept Gastroenterol, Nagasaki, Japan

[21] Hatano Red Cross Hosp, Dept Gastroenterol, Hatano, Japan

[22] Masuda Red Cross Hosp, Dept Gastroenterol, Masuda, Japan

[23] Fukaya Red Cross Hosp, Dept Gastroenterol, Saitama, Japan

[24] Japanese Red Cross Akita Hosp, Dept Gastroenterol, Akita, Japan

[25] Toyama Red Cross Hosp, Dept Gastroenterol, Toyama, Japan

来源：

JGH OPEN | 2024年 / 8卷 / 04期

关键词：

chronic hepatitis C; cirrhosis; glecaprevir and pibrentasvir (GLE/PIB); treatment periods;

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Background and aimIn patients with chronic hepatitis C, 8 weeks of glecaprevir and pibrentasvir (GLE/PIB) treatment for chronic hepatitis (non-cirrhosis) and 12 weeks for cirrhosis have been approved in Japan. However, whether 8 weeks of treatment for cirrhosis may reduce treatment efficacy has not been adequately investigated.MethodsThis prospective, nationwide, multicenter cohort study enrolled 1275 patients with chronic hepatitis C who received GLE/PIB therapy. The effect of liver fibrosis and treatment periods on the efficiency of GLE/PIB therapy was investigated. The primary endpoint was the sustained virological response (SVR) rate in patients with chronic hepatitis (non-cirrhosis) and cirrhosis. The association between treatment periods and liver fibrosis on the SVR after 12 weeks of treatment rate was investigated.ResultsThe SVR rates in patients with chronic hepatitis with 8 weeks of treatment, chronic hepatitis with 12 weeks of treatment, cirrhosis with 8 weeks of treatment, and cirrhosis with 12 weeks of treatment were 98.9% (800/809), 100% (87/87), 100% (166/166), and 99.1% (211/213), respectively, and were was not different among these groups (P = 0.4).ConclusionGLE/PIB therapy for chronic hepatitis C had high efficacy regardless of liver fibrosis status and treatment periods. Periods of GLE/PIB therapy could be chosen with available modalities, and high SVR rates could be achieved regardless of the decision. GLE/PIB therapy for chronic hepatitis C had high efficacy regardless of liver fibrosis status and treatment periods. Periods of GLE/PIB therapy could be chosen with available modalities, and high SVR rates could be achieved regardless of the decision. image

引用

页数：6

共 50 条

[31] Glecaprevir/Pibrentasvir: The Final Piece in the Hepatitis C Virus Treatment Puzzle?
Aghemo, Alessio
Colombo, Massimo
GASTROENTEROLOGY, 2018, 154 (04) : 1195 - 1196
[32] Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection
Toyoda, Hidenori
Chayama, Kazuaki
Suzuki, Fumitaka
Sato, Ken
Atarashi, Tomofumi
Watanabe, Tsunamasa
Atsukawa, Masanori
Naganuma, Atsushi
Notsumata, Kazuo
Osaki, Yukio
Nakamuta, Makoto
Takaguchi, Koichi
Saito, Satoru
Kato, Koji
Pugatch, David
Burroughs, Margaret
Redman, Rebecca
Alves, Katia
Pilot-Matias, Tami J.
Oberoi, Rajneet K.
Fu, Bo
Kumada, Hiromitsu
HEPATOLOGY, 2018, 67 (02) : 505 - 513
[33] Occult retinopathy following treatment of Hepatitis C with glecaprevir/pibrentasvir (Mavyret)
Massengill, Michael T.
Park, Jason C.
McAnany, J. Jason
Hyde, Robert A.
DOCUMENTA OPHTHALMOLOGICA, 2023, 146 (02) : 191 - 197
[34] Occult retinopathy following treatment of Hepatitis C with glecaprevir/pibrentasvir (Mavyret)
Michael T. Massengill
Jason C. Park
J. Jason McAnany
Robert A. Hyde
Documenta Ophthalmologica, 2023, 146 : 191 - 197
[35] Clinical outcomes of hepatitis C virus elimination using glecaprevir and pibrentasvir in hemodialysis patients: A multicenter study
Morishita, Asahiro
Ogawa, Chikara
Moriya, Akio
Tani, Joji
Yoneyama, Hirohito
Fujita, Koji
Oryu, Makoto
Senoo, Tomonori
Takaguchi, Koichi
Masaki, Tsutomu
HEPATOLOGY RESEARCH, 2020, 50 (05) : 557 - 564
[36] Efficacy and safety of Glecaprevir/Pibrentasvir in the treatment of mixed cryo-globulinemia due to chronic hepatitis C cirrhosis in a patient with chronic kidney disease
Papadopoulos, N.
Flouda, S.
Sveroni, E.
Palla, Tatarida M. C.
German, V
HIPPOKRATIA, 2019, 23 (01) : 30 - 32
[37] Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir: the SMART-C study
Dore, Gregory
Feld, Jordan
Thompson, Alexander
Martinello, Marianne
Muir, Andrew
Agarwal, Kosh
Mullhaupt, Beat
Wedemeyer, Heiner
Lacombe, Karine
Matthews, Gail
Schultz, Michael
Mercade, Gerard Estivill
Kho, Danny
Filep, Ecaterina
Petoumenos, Kathy
Marks, Pip
Tatsch, Fernando
dos Santos, Ana Gabriela Pires
Gane, Edward
JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E110 - E110
[38] A possible case of maculopapular eruption associated with glecaprevir/pibrentasvir treatment for chronic hepatitis C virus infection
Tomiyasu, Hiroka
Nakajima, Saeko
Kaku, Yo
Hirata, Masahiro
Kataoka, Tatsuki
Nomura, Takashi
Kabashima, Kenji
JOURNAL OF CUTANEOUS IMMUNOLOGY AND ALLERGY, 2021, 4 (04) : 93 - 95
[39] Chronic Hepatitis C Genotype 1-6 Glecaprevir/Pibrentasvir - again proven in Everyday Treatment
Warpakowski, Andrea
VISCERAL MEDICINE, 2019, 35 (03) : 195 - 195
[40] Histological improvement in chronic hepatitis C-autoimmune hepatitis overlap syndrome by glecaprevir and pibrentasvir
Kotaro Matsumoto
Kentaro Kikuchi
Yuta Namura
Ayako Watanabe
Hiromichi Tsunashima
Shinpei Doi
Clinical Journal of Gastroenterology, 2023, 16 : 572 - 579

← 1 2 3 4 5 →